Sorted By:

Relevance


Medicines in Development for Parkinson's Disease 2014 Report

PhRMA  |  Report

America’s biopharmaceutical research companies are currently developing 37 medicines to help the estimated 1.5 million Americans living with Parkinson’s Disease, a motor system disorder resulting from the loss of dopamine-producing brain cells. All of the medicines are either in clinical trials o...
https://www.phrma.org/report/medicines-in-development-for-parkinson-s-disease-2014-report

Medicare Monday: What you need to know about the latest Medicare Trustees report

PhRMA  |  Blog Post

For 2016, the Trustees report found that Medicare Part D beneficiaries increased generic drug use to 87 percent of all prescriptions – up from 86 percent in 2015 and 85 percent in 2014.
http://catalyst.phrma.org/what-you-need-to-know-about-the-latest-medicare-trustees-report

PhRMA Statement on 2016 Special 301 Report

PhRMA  |  Press Release

Sustained engagement is essential to promote meaningful reform of India’s patent laws and policies.
https://www.phrma.org/press-release/phrma-statement-on-2016-special-301-report

PhRMA Statement on 2015 Special 301 Report

PhRMA  |  Press Release

PhRMA members appreciate the prominent mention of these concerns in the Special 301 Report.
https://www.phrma.org/press-release/phrma-statement-on-2015-special-301-report

Medicines in Development for Osteoporosis 2016 Report

PhRMA  |  Report

Osteoporosis causes loss of bone mass and deterioration of bone structure, leading to fragile and easily fractured bones. Although osteoporosis mainly affects women, men are also at risk for the disease. In fact, half of women and a quarter of men over the age of 50 will break a bone due to osteo...
https://www.phrma.org/report/medicines-in-development-for-osteoporosis-2016-report

Share the Savings

PhRMA  |  From PhRMA

Explore our reports below to get the facts about where the discounts are going.
https://www.phrma.org/media/discounts-reports

Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines

PhRMA  |  Blog Post

Learn more about Part B at PhRMA.org/PartB and find the report here.
http://catalyst.phrma.org/medicare-monday-new-report-highlights-progress-in-fighting-cancer-with-new-physician-administered-medicines

Medicines in Development for Diabetes 2016 Report

PhRMA  |  Report

View the full report below and explore additional resources to learn more about the important work being done to combat diabetes.  
https://www.phrma.org/report/medicines-in-development-for-diabetes2

New Report Shows 74 Percent of Medicines in Development have Potential to be First-in-Class Treatments

PhRMA  |  Press Release

To view the full Pipeline report: http://phrmasubscribers.com/2017-pipeline-report To view the executive summary: www.phrma.org/biopharma-pipeline-report   About PhRMA The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.
https://www.phrma.org/press-release/new-report-shows-74-percent-of-medicines-in-development-have-potential-to-be-first-in-class-treatments

4 Things to know about the QuintilesIMS Medicines Use and Spending in the U.S. report

PhRMA  |  Blog Post

Here are four things you should know about the latest QuintilesIMS report: After accounting for discounts and rebates, spending on medicines grew just 4.8 percent in 2016.
http://catalyst.phrma.org/4-things-to-know-about-the-quintilesims-medicines-use-and-spending-in-the-us-report

Medicines in Development for Immuno-Oncology 2017 Report

PhRMA  |  Report

More than 240 immuno-oncology treatments in development are accelerating progress for patients with cancer. The rapid pace of scientific advances has helped usher in a new era of medicine for cancer patients over the last decade. Biopharmaceutical researchers’ understanding of the underlying biol...
https://www.phrma.org/medicines-in-development-immuno-oncology

New Report Shows More than 240 Immuno-Oncology Treatments in Development for Patients with Cancer

PhRMA  |  Press Release

The full “Medicines in Development for Immuno-Oncology” report can be downloaded here.
https://www.phrma.org/press-release/new-report-shows-more-than-240-immuno-oncology-treatments-in-development-for-patients-with-cancer

Medicines in Development for Vaccines 2017 Update

PhRMA  |  Report

Download the report to learn more.
https://www.phrma.org/vaccines-2017-report

Medicines in Development for Women 2013 Report

PhRMA  |  Report

In separate reports, PhRMA has found that researchers are working on 299 medicines for heart disease and stroke, which kill nearly a half-million women each year, and 98 medicines for lung cancer, the leading cancer killer of women (see page 60 for details).
https://www.phrma.org/report/medicines-in-development-for-women

2014 Economic Futures Report

PhRMA  |  Press Release

The report uniquely combines quantitative data with input from industry leaders, resulting in a more complete picture of the potential growth trajectories facing the industry. 
https://www.phrma.org/press-release/2014-economic-futures-report

List of 2017 Medicines in Development for Alzheimer's

PhRMA  |  Report

This report outlines the medicines in development for Alzheimer's Disease including the drug name, sponsor, indication and development phase.
https://www.phrma.org/report/list-of-2017-medicines-in-development-for-alzheimer-s

Economic Impact Report

PhRMA  |  Report

At a time when the economic competitiveness at the national and state level is recognized to be strongly rooted in the capacity to advance innovation-based industries, the U.S. biopharmaceutical industry stands out as a leading research and development (R&D) and advanced manufacturing industr...
https://www.phrma.org/report/economic-impact-report

PhRMA Statement on HELP Committee Health Reform Vote

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/phrma-statement-on-help-committee-health-reform-vote

Tauzin Attends White House Health Reform Summit

PhRMA  |  Press Release

Industry-wide research and investment reached a record $58.8 billion in 2007.
https://www.phrma.org/press-release/tauzin-attends-white-house-health-reform-summit

PhRMA Statement on Consumer Reports Study

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/phrma-statement-on-consumer-reports-study

PhRMA Statement on 2014 Special 301 Report

PhRMA  |  Press Release

PhRMA appreciates the fact that USTR has raised these concerns in the Report.
https://www.phrma.org/press-release/phrma-statement-on-2014-special-301-report

New Report Shows Record Number of Medicines Currently in Development to Treat Mental Illness

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/new-report-shows-record-number-of-medicines-currently-in-development-to-treat-mental-illness

New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/new-report-shows-record-number-of-medicines-currently-in-development-to-treat-diabetes

The Biopharmaceutical Pipeline

PhRMA  |  Report

Download the Executive Summary Download the Full Report
https://www.phrma.org/report/the-biopharmaceutical-pipeline

New Report Shows How Supply Chain Shapes Brand-Name Medicine Prices

PhRMA  |  Press Release

View the full report here and patient examples here.
https://www.phrma.org

You have reviewed the first 50 results out of 1032. Each page contains 25 results. You're on page 2.

prev 1 2 3 4 5 6 next